In a performance setting, Cytomel doses will be very similar to hypothyroidism treatment plans. The individual will normally begin with 25mcg per day and increase the total dose -25mcg every 2-4 weeks as needed. Most will find they will have no need to go above 75-100mcg per day, with the 125mcg per day range being acceptable for very short periods of time. Such a high dose might be acceptable at the end of a harsh contest diet but should not be a regular dose through the brunt of the diet. As for total use, 6-8 weeks will be the safest total duration. Longer can be acceptable, such as 8-12 weeks, but it does increase the risk of thyroid dependency. However, most healthy adults should not have an issue. Once you have reached your high end dose and it’s time to come off, you are encouraged to drop the dose down to 25mcg per day and hold at that dose for 7-10 days. This will allow the body to adjust and protect you from falling into hypothyroidism. For no reason should you discontinue use abruptly, the 7-10 day low dose is imperative.
The medical information provided in this site is for educational purposes only and is the property of the American Osteopathic College of Dermatology. It is not intended nor implied to be a substitute for professional medical advice and shall not create a physician - patient relationship. If you have a specific question or concern about a skin lesion or disease, please consult a dermatologist. Any use, re-creation, dissemination, forwarding or copying of this information is strictly prohibited unless expressed written permission is given by the American Osteopathic College of Dermatology.
Nurses need to be aware of the myriad adverse effects that can occur with immunotherapies, and recognize that many of them can occur long after treatment has concluded. This means that patient teaching and ongoing follow-up to assess for these effects are crucial. Current sources point to the importance of early detection and interventions for the management of adverse effects to prevent more severe negative patient outcomes. As opposed to some other sources, these authors recommend against “knee jerk” implementation of systemic corticosteroids for diarrhea because such treatment may mask the development of severe colitis.